Angiogenic imbalances: the obstetric perspective

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 1, 2010, Pages 17.e1-17.e8

  Espinoza, Jimmy ^a   Uckele, John E ^a   Starr, Robert A ^a   Seubert, David E ^a   Espinoza, Andres F ^a   Berry, Stanley M ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

angiogenic imbalance; endoglin; Mirror syndrome; molar; ovarian hyperstimulation syndrome; preeclampsia; sFlt 1; vascular endothelial growth factor (VEGF)

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ARTICLE; CHORION VILLUS; DISEASE ASSOCIATION; DISEASE SEVERITY; EDEMA; FETUS HYDROPS; GENE EXPRESSION; HUMAN; HYDATIDIFORM MOLE; INTRAUTERINE GROWTH RETARDATION; MATERNAL SERUM; OVARY HYPERSTIMULATION; PLACENTA; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY TOXEMIA; PRIORITY JOURNAL; TROPHOBLAST; TROPHOBLASTIC DISEASE;

EID: 77953912998     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.10.891     Document Type: Article

References (153)

1. Vogel R.A. Cholesterol lowering and endothelial function. Am J Med 107 (1999) 479-487
2. Park J.E., Chen H.H., Winer J., Houck K.A., and Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269 (1994) 25646-25654
3. Gale N.W., and Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13 (1999) 1055-1066
4. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
5. Matsumoto T., and Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE 2001 (2001) RE21
6. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
8. Luttun A., and Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered?. J Clin Invest 111 (2003) 600-602
9. Barleon B., Reusch P., Totzke F., et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 4 (2001) 143-154
10. Clark D.E., Smith S.K., He Y., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 59 (1998) 1540-1548
11. Torry D.S., Wang H.S., Wang T.H., Caudle M.R., and Torry R.J. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 179 (1998) 1539-1544
12. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003) 649-658
13. Koga K., Osuga Y., Yoshino O., et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 88 (2003) 2348-2351
14. Krauss T., Pauer H.U., and Augustin H.G. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 23 (2004) 101-111
15. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004) 672-683
16. Chaiworapongsa T., Romero R., Kim Y.M., et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 17 (2005) 3-18
17. Redman C.W., and Sargent I.L. Latest advances in understanding preeclampsia. Science 308 (2005) 1592-1594
18. Bdolah Y., Karumanchi S.A., and Sachs B.P. Recent advances in understanding of preeclampsia. Croat Med J 46 (2005) 728-736
19. Robinson C.J., Johnson D.D., Chang E.Y., Armstrong D.M., and Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol 195 (2006) 255-259
20. Crispi F., Dominguez C., Llurba E., Martin-Gallan P., Cabero L., and Gratacos E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol 195 (2006) 201-207
21. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006) 992-1005
22. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 (2006) 642-649
23. Boutsikou T., Malamitsi-Puchner A., Economou E., Boutsikou M., Puchner K.P., and Hassiakos D. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev 82 (2006) 235-239
24. Wallner W., Sengenberger R., Strick R., et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 112 (2007) 51-57
25. Espinoza J., Romero R., Nien J.K., et al. A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). J Matern Fetal Neonatal Med 19 (2006) 607-613
26. Rana S., Venkatesha S., DePaepe M., Chien E.K., Paglia M., and Karumanchi S.A. Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol 109 (2007) 549-552
27. Kusanovic J.P., Romero R., Espinoza J., et al. Twin-to-twin transfusion syndrome: an antiangiogenic state?. Am J Obstet Gynecol 198 (2008) 382-388
28. Espinoza J., Chaiworapongsa T., Romero R., et al. Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med 20 (2007) 495-507
29. Espinoza J., Uckele J.E., Starr R.A., Lorenz R.P., Bronsteen R.A., and Berry S.M. Insights into angiogenic imbalances during pregnancy. Obstet Gynecol 114 (2009) 437-440
30. Zhou Y., McMaster M., Woo K., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160 (2002) 1405-1423
31. Tsatsaris V., Goffin F., Munaut C., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88 (2003) 5555-5563
32. Levine R.J., and Karumanchi S.A. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 48 (2005) 372-386
33. Aggarwal P.K., Jain V., Sakhuja V., Karumanchi S.A., and Jha V. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int 69 (2006) 621-624
34. Signore C., Mills J.L., Qian C., et al. Circulating angiogenic factors and placental abruption. Obstet Gynecol 108 (2006) 338-344
35. Young B., Levine R.J., Salahuddin S., et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med (2009) 1-6
36. Stepan H., and Faber R. Elevated sFlt1 level and preeclampsia with parvovirus-induced hydrops. N Engl J Med 354 (2006) 1857-1858
37. Kallen B. Maternal morbidity and mortality in in-vitro fertilization. Best Pract Res Clin Obstet Gynaecol 22 (2008) 549-558
38. Kallen B., Finnstrom O., Nygren K.G., Otterblad O.P., and Wennerholm U.B. In vitro fertilisation in Sweden: obstetric characteristics, maternal morbidity and mortality. BJOG 112 (2005) 1529-1535
39. Makris A., Thornton C., Thompson J., et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 71 (2007) 977-984
40. Gilbert J.S., Babcock S.A., and Granger J.P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50 (2007) 1142-1147
41. Lyall F., Greer I.A., Boswell F., and Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. BJOG 104 (1997) 223-228
42. Kupferminc M.J., Daniel Y., Englender T., et al. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 38 (1997) 302-306
43. McKeeman G.C., Ardill J.E., Caldwell C.M., Hunter A.J., and McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 191 (2004) 1240-1246
44. Chaiworapongsa T., Romero R., Espinoza J., et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award. Am J Obstet Gynecol 190 (2004) 1541-1547
45. Maynard S.E., Venkatesha S., Thadhani R., and Karumanchi S.A. Soluble fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 57 (2005) 1R-7R
46. Levine R.J., Thadhani R., Qian C., et al. Urinary placental growth factor and risk of preeclampsia. JAMA 293 (2005) 77-85
47. Rajakumar A., Michael H.M., Rajakumar P.A., et al. Extra-placental expression of vascular endothelial growth factor receptor-1 (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 26 (2005) 563-573
48. Shibata E., Rajakumar A., Powers R.W., et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 90 (2005) 4895-4903
49. Staff A.C., Braekke K., Harsem N.K., Lyberg T., and Holthe M.R. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 122 (2005) 33-39
50. Wolf M., Shah A., Lam C., et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 193 (2005) 16-22
51. Bdolah Y., Lam C., Rajakumar A., et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?. Am J Obstet Gynecol 198 (2008) 428-436
52. Jeyabalan A., Powers R.W., Durica A.R., Harger G.F., Roberts J.M., and Ness R.B. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia. Am J Hypertens 21 (2008) 943-947
53. Mehendale R., Hibbard J., Fazleabas A., and Leach R. Placental angiogenesis markers sFlt-1 and PlGF: response to cigarette smoke. Am J Obstet Gynecol 197 (2007) 363-365
54. American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG practice bulletin, no. 33. Int J Gynaecol Obstet 77 (2002) 67-75
55. Masuyama H., Suwaki N., Nakatsukasa H., Masumoto A., Tateishi Y., and Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 194 (2006) 551-556
56. Ohkuchi A., Hirashima C., Matsubara S., et al. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria. Hypertens Pregnancy 28 (2009) 95-108
57. Holston A.M., Qian C., Yu K.F., Epstein F.H., Karumanchi S.A., and Levine R.J. Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol 200 (2009) 392.e1-392.e10
58. Sibai B.M., and Stella C.L. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 200 (2009) 481-487
59. Chaiworapongsa T., Espinoza J., Gotsch F., et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 21 (2008) 25-40
60. Malamitsi-Puchner A., Boutsikou T., Economou E., et al. Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators Inflamm 2005 (2005) 293-297
61. Girardi G., Yarilin D., Thurman J.M., Holers V.M., and Salmon J.E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 203 (2006) 2165-2175
62. Padavala S., Pope N., Baker P., and Crocker I. An imbalance between vascular endothelial growth factor and its soluble receptor in placental villous explants of intrauterine growth-restricted pregnancies. J Soc Gynecol Investig 13 (2006) 40-47
63. Sandrim V.C., Palei A.C., Cavalli R.C., et al. Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod 15 (2009) 115-120
64. Tjoa M.L., van Vugt J.M., Mulders M.A., Schutgens R.B., Oudejans C.B., and van Wijk I.J. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 98 (2001) 600-607
65. Tidwell S.C., Ho H.N., Chiu W.H., Torry R.J., and Torry D.S. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 184 (2001) 1267-1272
66. Chappell L.C., Seed P.T., Briley A., et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 187 (2002) 127-136
67. Taylor R.N., Grimwood J., Taylor R.S., McMaster M.T., Fisher S.J., and North R.A. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 188 (2003) 177-182
68. Polliotti B.M., Fry A.G., Saller D.N., Mooney R.A., Cox C., and Miller R.K. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 101 (2003) 1266-1274
69. Parra M., Rodrigo R., Barja P., et al. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 193 (2005) 1486-1491
70. Moore Simas T.A., Crawford S.L., Solitro M.J., Frost S.C., Meyer B.A., and Maynard S.E. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 197 (2007) 244-248
71. Ohkuchi A., Hirashima C., Matsubara S., et al. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 30 (2007) 151-159
72. Poon L.C., Zaragoza E., Akolekar R., Anagnostopoulos E., and Nicolaides K.H. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 28 (2008) 1110-1115
73. Erez O., Romero R., Espinoza J., et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 21 (2008) 279-287
74. Poon L.C., Kametas N.A., Maiz N., Akolekar R., and Nicolaides K.H. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 53 (2009) 812-818
75. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 89 (2004) 770-775
76. Rana S., Karumanchi S.A., Levine R.J., et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50 (2007) 137-142
77. Baumann M.U., Bersinger N.A., Mohaupt M.G., Raio L., Gerber S., and Surbek D.V. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 199 (2008) 266
78. Romero R., Nien J.K., Espinoza J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21 (2008) 9-23
79. Schmidt M., Dogan C., Birdir C., et al. Placental growth factor: a predictive marker for preeclampsia?. Gynakol Geburtshilfliche Rundsch 49 (2009) 94-99
80. Espinoza J., Romero R., Nien J.K., et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 196 (2007) 326.e1-326.e13
81. Stepan H., Geipel A., Schwarz F., Kramer T., Wessel N., and Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 198 (2008) 175-176
82. O'Driscoll D.T. A fluid retention syndrome associated with severe isoimmunization in the rhesus factor. J Obstet Gynaecol Br Emp 63 (1956) 372-374
83. Goodlin R.C. Impending fetal death in utero due to isoimmunization. Obstet Gynecol 10 (1957) 299-302
84. Scott J.S. Pregnancy toxaemia associated with hydrops foetalis, hydatidiform mole and hydramnios. J Obstet Gynaecol Br Emp 65 (1958) 689-701
85. Cohen A. Maternal syndrome in Rh iso-immunization: report of a case. J Obstet Gynaecol Br Emp 67 (1960) 325-327
86. Hirsch M.R., and Mark M.S. Pseudotoxemia and erythroblastosis: report of a case. Obstet Gynecol 24 (1964) 47-48
87. John A.H., and Duncan A.S. The maternal syndrome associated with hydrops foetalis. J Obstet Gynaecol Br Commonw 71 (1964) 61-65
88. Quagliarello J.R., Passalaqua A.M., Greco M.A., Zinberg S., and Young B.K. Ballantyne's triple edema syndrome: prenatal diagnosis with ultrasound and maternal renal biopsy findings. Am J Obstet Gynecol 132 (1978) 580-581
89. Duthie S.J., and Walkinshaw S.A. Parvovirus associated fetal hydrops: reversal of pregnancy induced proteinuric hypertension by in utero fetal transfusion. BJOG 102 (1995) 1011-1013
90. Carbillon L., Oury J.F., Guerin J.M., Azancot A., and Blot P. Clinical biological features of Ballantyne syndrome and the role of placental hydrops. Obstet Gynecol Surv 52 (1997) 310-314
91. Ordorica S.A., Marks F., Frieden F.J., Hoskins I.A., and Young B.K. Aneurysm of the vein of Galen: a new cause for Ballantyne syndrome. Am J Obstet Gynecol 162 (1990) 1166-1167
92. Midgley D.Y., and Harding K. The Mirror syndrome. Eur J Obstet Gynecol Reprod Biol 88 (2000) 201-202
93. Finamore P.S., Kontopoulos E., Price M., Giannina G., and Smulian J.C. Mirror syndrome associated with sacrococcygeal teratoma: a case report. J Reprod Med 52 (2007) 225-227
94. Dorman S.L., and Cardwell M.S. Ballantyne syndrome caused by a large placental chorioangioma. Am J Obstet Gynecol 173 (1995) 1632-1633
95. Barker G., Boyd R.D., D'Souza S.W., Donnai P., Fox H., and Sibley C.P. Placental water content and distribution. Placenta 15 (1994) 47-56
96. Kovalovszki L., Villanyi E., and Benko G. Placental villous edema: a possible cause of antenatal hypoxia. Acta Paediatr Hung 30 (1990) 209-215
97. Naeye R.L., Maisels M.J., Lorenz R.P., and Botti J.J. The clinical significance of placental villous edema. Pediatrics 71 (1983) 588-594
98. Alvarez H., Sala M.A., and Benedetti W.L. Intervillous space reduction in the edematous placenta. Am J Obstet Gynecol 112 (1972) 819-820
99. Stepan H., and Faber R. Cytomegalovirus-induced mirror syndrome associated with elevated levels of angiogenic factors. Obstet Gynecol 109 (2007) 1205-1206
100. Koga K., Osuga Y., Tajima T., et al. Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 94 (2010) 305-308
101. Soto-Wright V., Bernstein M., Goldstein D.P., and Berkowitz R.S. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 86 (1995) 775-779
102. Jauniaux E. Partial moles: from postnatal to prenatal diagnosis. Placenta 20 (1999) 379-388
103. Prasannan-Nair C., Reynolds S.F., and Budden G. Partial molar pregnancy with severe pre-eclampsia at 19 weeks' gestation. J Obstet Gynaecol 26 (2006) 817
104. Stefos T., Plachouras N., Mari G., Cosmi E., and Lolis D. A case of partial mole and atypical type I triploidy associated with severe HELLP syndrome at 18 weeks' gestation. Ultrasound Obstet Gynecol 20 (2002) 403-404
105. Sherer D.M., Dalloul M., Stimphil R., et al. Acute onset of severe hemolysis, elevated liver enzymes, and low platelet count syndrome in a patient with a partial hydatidiform mole at 17 weeks gestation. Am J Perinatol 23 (2006) 163-166
106. Benirschke K., Kaufmann P., and Baergen R. Pathology of the human placenta. 5th ed. (2006), Springer-Verlag, New York
107. Qiao S., Nagasaka T., and Nakashima N. Numerous vessels detected by CD34 in the villous stroma of complete hydatidiform moles. Int J Gynecol Pathol 16 (1997) 233-238
108. Richani K., Romero R., Kim Y.M., et al. Tissue microarray: an effective high-throughput method to study the placenta for clinical and research purposes. J Matern Fetal Neonatal Med 19 (2006) 509-515
109. Rasmussen S., and Irgens L.M. Fetal growth and body proportion in preeclampsia. Obstet Gynecol 101 (2003) 575-583
110. Aardema M.W., Saro M.C., Lander M., de Wolf B.T., Oosterhof H., and Aarnoudse J.G. Second trimester Doppler ultrasound screening of the uterine arteries differentiates between subsequent normal and poor outcomes of hypertensive pregnancy: two different pathophysiological entities?. Clin Sci (Lond) 106 (2004) 377-382
111. Harrington K., Cooper D., Lees C., Hecher K., and Campbell S. Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Ultrasound Obstet Gynecol 7 (1996) 182-188
112. Albaiges G., Missfelder-Lobos H., Lees C., Parra M., and Nicolaides K.H. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 96 (2000) 559-564
113. Papageorghiou A.T., Yu C.K., Cicero S., Bower S., and Nicolaides K.H. Second-trimester uterine artery Doppler screening in unselected populations: a review. J Matern Fetal Neonatal Med 12 (2002) 78-88
114. Papageorghiou A.T., Yu C.K., Bindra R., Pandis G., and Nicolaides K.H. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 18 (2001) 441-449
115. Kumazaki K., Nakayama M., Suehara N., and Wada Y. Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathologic conditions. Hum Pathol 33 (2002) 1069-1077
116. Kusanovic J.P., Romero R., Gotsch F., et al. Discordant placental echogenicity: a novel sign of impaired placental perfusion in twin-twin transfusion syndrome?. J Matern Fetal Neonatal Med 23 (2010) 103-106
117. Nagamatsu T., Fujii T., Kusumi M., et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145 (2004) 4838-4845
118. Munaut C., Lorquet S., Pequeux C., et al. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 23 (2008) 1407-1415
119. Versen-Hoynck F., Rajakumar A., Bainbridge S.A., Gallaher M.J., Roberts J.M., and Powers R.W. Human placental adenosine receptor expression is elevated in preeclampsia and hypoxia increases expression of the A2A receptor. Placenta 30 (2009) 434-442
120. de Ponti C., Carini R., Alchera E., et al. Adenosine A2a receptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages. J Leukoc Biol 82 (2007) 392-402
121. Moldenhauer J.S., Stanek J., Warshak C., Khoury J., and Sibai B. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent. Am J Obstet Gynecol 189 (2003) 1173-1177
122. Zhang P., Schmidt M., and Cook L. Maternal vasculopathy and histologic diagnosis of preeclampsia: poor correlation of histologic changes and clinical manifestation. Am J Obstet Gynecol 194 (2006) 1050-1056
123. Benirschke K., and Kaufmann P. Maternal diseases complicating pregnancy: diabetes, tumors, preeclampsia, lupus anticoagulant. In: Benirschke K., and Kaufmann P. (Eds). Pathology of the human placenta (2000), Springer-Verlag, New York 523-589
124. Constancia M., Hemberger M., Hughes J., et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature 417 (2002) 945-948
125. Giudice L.C. Maternal-fetal conflict: lessons from a transgene. J Clin Invest 110 (2002) 307-309
126. Odegard R.A., Vatten L.J., Nilsen S.T., Salvesen K.A., and Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 96 (2000) 950-955
127. Xiong X., Demianczuk N.N., Buekens P., and Saunders L.D. Association of preeclampsia with high birth weight for age. Am J Obstet Gynecol 183 (2000) 148-155
128. Xiong X., and Fraser W.D. Impact of pregnancy-induced hypertension on birthweight by gestational age. Paediatr Perinat Epidemiol 18 (2004) 186-191
129. Schlembach D., Wallner W., Sengenberger R., et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 29 (2007) 407-413
130. Heyborne K.D., and Chism D.M. Reversal of Ballantyne syndrome by selective second-trimester fetal termination: a case report. J Reprod Med 45 (2000) 360-362
131. Pirhonen J.P., and Hartgill T.W. Spontaneous reversal of mirror syndrome in a twin pregnancy after a single fetal death. Eur J Obstet Gynecol Reprod Biol 116 (2004) 106-107
132. Sarhanis P., and Pugh D.H. Resolution of pre-eclampsia following intrauterine death of one twin. BJOG 99 (1992) 159-160
133. Hagay Z.J., Levy R., Zalel Y., and Weissman A. Single fetal demise in twin gestation resulting in the resolution of severe pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 56 (1994) 137-138
134. Audibert F., Salomon L.J., Castaigne-Meary V., Alves K., and Frydman R. Selective termination of a twin pregnancy as a treatment of severe pre-eclampsia. BJOG 110 (2003) 68-69
135. Heyborne K.D., and Porreco R.P. Selective feticide reverses preeclampsia in discordant twins. Am J Obstet Gynecol 191 (2004) 477-480
136. Yoneyama Y., Sawa R., Suzuki S., Shin S., Power G.G., and Araki T. The relationship between uterine artery Doppler velocimetry and umbilical venous adenosine levels in pregnancies complicated by preeclampsia. Am J Obstet Gynecol 174 (1996) 267-271
137. Alchera E., Tacchini L., Imarisio C., et al. Adenosine-dependent activation of hypoxia-inducible factor-1 induces late preconditioning in liver cells. Hepatology 48 (2008) 230-239
138. Merighi S., Benini A., Mirandola P., et al. A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia 7 (2005) 894-903
139. Nevo O., Soleymanlou N., Wu Y., et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 291 (2006) R1085-R1093
140. Jeyabalan A., McGonigal S., Gilmour C., Hubel C.A., and Rajakumar A. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 29 (2008) 555-563
141. Lin S., Shimizu I., Suehara N., Nakayama M., and Aono T. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol 85 (1995) 760-765
142. Olofsson P., Laurini R.N., and Marsal K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol 49 (1993) 161-168
143. Aardema M.W., Oosterhof H., Timmer A., van Rooy I., and Aarnoudse J.G. Uterine artery Doppler flow and uteroplacental vascular pathology in normal pregnancies and pregnancies complicated by pre-eclampsia and small for gestational age fetuses. Placenta 22 (2001) 405-411
144. Madazli R., Somunkiran A., Calay Z., Ilvan S., and Aksu M.F. Histomorphology of the placenta and the placental bed of growth restricted foetuses and correlation with the Doppler velocimetries of the uterine and umbilical arteries. Placenta 24 (2003) 510-516
145. Voigt H.J., and Becker V. Doppler flow measurements and histomorphology of the placental bed in uteroplacental insufficiency. J Perinat Med 20 (1992) 139-147
146. Espinoza J., Romero R., Mee K.Y., et al. Normal and abnormal transformation of the spiral arteries during pregnancy. J Perinat Med 34 (2006) 447-458
147. Pijnenborg R., Vercruysse L., and Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta 27 (2006) 939-958
148. Kosaka K., Fujiwara H., Yoshioka S., and Fujii S. Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod 22 (2007) 1647-1651
149. Pau E., Alonso-Muriel I., Gomez R., et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 21 (2006) 1453-1460
150. Gomez R., Simon C., Remohi J., and Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 68 (2003) 2164-2171
151. Gomez R., Simon C., Remohi J., and Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 143 (2002) 4339-4348
152. Luttun A., Tjwa M., and Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci 979 (2002) 80-93
153. Li Z., Zhang Y., Ying M.J., et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50 (2007) 686-692